Cargando…
Pazopanib, a promising option for the treatment of aggressive fibromatosis
Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of agents are used. Tyrosine kinase inhibitors have recently been reported to show us...
Autores principales: | Szucs, Zoltan, Messiou, Christina, Wong, Han Hsi, Hatcher, Helen, Miah, Aisha, Zaidi, Shane, van der Graaf, Winette T.A., Judson, Ian, Jones, Robin L., Benson, Charlotte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469564/ https://www.ncbi.nlm.nih.gov/pubmed/28099210 http://dx.doi.org/10.1097/CAD.0000000000000474 |
Ejemplares similares
-
Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis
por: Martin-Liberal, Juan, et al.
Publicado: (2013) -
Pazopanib: a novel treatment option for aggressive fibromatosis
por: Bulut, Gulcan, et al.
Publicado: (2016) -
Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response
por: Libertini, M., et al.
Publicado: (2018) -
Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience
por: Maruzzo, Marco, et al.
Publicado: (2015) -
Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care?
por: Husson, Olga, et al.
Publicado: (2018)